Cancer coalition aims to boost access to medicines in poorer countries




  • In US
  • 2022-05-20 06:13:43Z
  • By Reuters

By Jennifer Rigby

LONDON (Reuters) - Pharmaceutical companies including Novartis and Roche have teamed up with global cancer organisations in an alliance aimed at getting more oncology medications to poorer countries.

Currently, fewer than 50% of the cancer drugs on the World Health Organization's (WHO) essential medicines list are available in low and middle income countries, and the disease burden is growing. Without action, almost three in four cancer deaths are set to occur in these settings in the next decade.

In the first concrete step for the Access to Oncology Medicines (ATOM) Coalition, Novartis has licensed its blood cancer drug nilotinib to the United Nations' Medicines Patent Pool (MPP), allowing generic manufacturers to access the know-how to produce the drug at scale and at a lower cost.

Previously, the technology behind HIV drugs and COVID-19 has been shared in this way, but nilotinib is the first drug for a non-communicable disease in the pool, ATOM said.

It only has a year left on its patent, but Novartis' head of global health Lutz Hegemann said generic manufacturers had signalled it was still worthwhile.

"I think in a year there's a lot that you can try to test and this is not the only medicine that we would consider offering up," he said in an interview.

The aim of the coalition is not just to provide the drugs but also support training, diagnostics and delivery to get them to patients, the Union for International Cancer Control - a key partner - said.

The coalition begins with $32 million from the private sector and will focus initially on capacity building activities in ten lower and middle income countries, developing existing initiatives.

The Access to Medicine Foundation, which has long called out the inequality in access to drugs and care, will collaborate with the group.

"You've got some of the top minds ... the people with deep pockets, the shelves stocked with drugs .... We will be tracking progress on how this consortium delivers," said Jayasree Iyer, director of the foundation.

(Reporting by Jennifer Rigby; Editing by Mark Potter)

COMMENTS

More Related News

Novartis leans toward spinoff of generic drugs unit - Bloomberg News
Novartis leans toward spinoff of generic drugs unit - Bloomberg News
  • US
  • 2022-06-30 16:19:55Z

A challenging macro environment for leveraged buyouts has made the sale route difficult and Novartis sees a separate listing of the Sandoz business as more...

WHO: COVID-19 cases rising nearly everywhere in the world
WHO: COVID-19 cases rising nearly everywhere in the world
  • US
  • 2022-06-30 10:28:03Z

The number of new coronavirus cases rose by 18% in the last week, with more than 4.1 million cases reported globally, according to the World Health...

Turkey records first case of monkeypox - health minister
Turkey records first case of monkeypox - health minister

Turkey has detected its first case of monkeypox in a 37-year-old patient who is in isolation, Health Minister Fahrettin Koca said on Thursday. The virus has...

Novartis resumes production of radioligand therapy medicines
Novartis resumes production of radioligand therapy medicines
  • US
  • 2022-06-30 05:33:27Z

Novartis said it resumed the production and delivery of radioligand therapy medicines after fixing the issues that had led to a temporary suspension of...

Senate Democrats see
Senate Democrats see 'major progress' on Biden agenda bill, hope for July vote

Senate Democrats are close to a deal to lower prescription drug costs as part of a larger party-line package to advance a number of Biden's economic...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US